Teucrium Corn Fund vs Revvity Inc — how do they compare? Teucrium Corn Fund trades at $18.42 (market cap $125.39M), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 135.4× Teucrium Corn Fund's market cap, and Revvity Inc pays a 0.18% dividend while Teucrium Corn Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Corn Fund for 27 Days and Revvity Inc for 12 Days on average.
| CORN | RVTY | |
|---|---|---|
Market Cap | $125.39M | $16.98B |
Volume | 271,634 | 1,456,900 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $20.29 | $157.36 |
52-Week Low | $16.46 | $82.26 |
Typical Hold Time | 27 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
CORN (Teucrium Corn Fund) is trading at $18.42, down 3.31% with bearish technical indicators showing 13 sell signals versus 7 buy signals. The fund recently demonstrated strong performance with a 9.7% return in July 2026, outperforming broader markets. Current technical analysis indicates oversold conditions with RSI at 29.02, while moving averages remain bearish. Agricultural commodities face mixed sentiment amid ongoing inflation concerns and geopolitical tensions affecting global supply chains.
The outlook for CORN reflects commodity market volatility with potential upside from agricultural sector strength but significant downside risk from macroeconomic pressures. Investment opportunity exists in agricultural commodity exposure, though risks include inflation trajectory, Federal Reserve policy, and geopolitical conflicts that could disrupt global corn markets and fund performance.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →